NCT05243628 - Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions

Type 1 Diabetes

Interventions

BIOLOGICAL

Afrezza (insulin human) Inhalation Powder

"Pharmaceutical form: powder~Route of administration: inhalation"

BIOLOGICAL

insulin degludec

"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"

DEVICE

Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)

Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ

Trial Locations (2)

Texas Diabetes and Endocrinology, Austin

Diabetes Treatment Center, Loma Linda University, Loma Linda